Myriad Genetics grants stock options to executives

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Executive Retention Stock Option Awards

On November 6, 2026, the Compensation and Human Capital Committee (the "Committee") of the Board of Directors (the "Board") of Myriad Genetics, Inc. (the "Company") approved one-time equity awards in the form of stock options (the "Retention Option Awards") for certain executive officers of the Company, including its named executive officers¹, in order to promote the retention and continuity of the Company's leadership as the Company executes on initiatives designed to improve operational efficiencies and financial performance.²

The Retention Option Awards were granted under the Company's 2026 Employee, Director and Consultant Equity Incentive Plan (the "2026 Plan").³ Retention Option Awards received by the Company's named executive officers, and the number of shares subject to such awards, are set forth in the table below:

Named Executive Officer

Title

Shares Subject to Retention Option Award

Benjamin R. Wheeler

Chief Financial Officer

121,379

Mark S. Verratti

Chief Operating Officer

146,933

Dale Muzzey

Chief Scientific Officer

92,632

Each Retention Option Award covers shares of the Company's common stock, par value $0.01 per share⁴, and has an exercise price per share equal to the closing price of the Company's common stock on the grant date.⁵ The Retention Option Awards will vest and become exercisable on the third anniversary of the grant date, subject to the recipient's continued service with the Company through such vesting date⁶ and the terms and conditions of the 2026 Plan and the related stock option agreement.

Each Retention Option Award will have a term of ten years⁶, subject to earlier termination in accordance with the terms of the 2026 Plan and the related stock option agreement. Under the related stock option agreement, if a recipient's service terminates other than due to death, disability or termination for cause, any vested portion of the option generally may remain exercisable for three months following termination. Upon a termination for cause, the option will terminate immediately, whether or not vested. In the event of the recipient's termination of employment, the Retention Option Awards will be subject to the terms of the recipient's applicable Severance and Change in Control Agreement with the Company.

The foregoing description of the Retention Option Awards is qualified in its entirety by reference to the form of stock option agreement under the 2026 Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Exhibit

Number

Description

10.1 Form of Stock Option Agreement under the 2026 Employee, Director and Consultant Equity Incentive Plan.⁷

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: November 9, 2026

By:

/s/ Benjamin R. Wheeler

Benjamin R. Wheeler

Chief Financial Officer